ERBIN:: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor

被引:256
|
作者
Borg, JP
Marchetto, S
Le Bivic, A
Ollendorff, V
Jaulin-Bastard, F
Saito, H
Fournier, E
Adélaïde, J
Margolis, B
Birnbaum, D
机构
[1] INSERM, U119, F-13009 Marseille, France
[2] Fac Sci Luminy, IBDM, F-13288 Marseille 09, France
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA
关键词
D O I
10.1038/35017038
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ERBB receptors have a crucial role in morphogenesis and oncogenesis. We have identified a new PDZ protein we named ERBIN (ERBB2 interacting protein) that acts as an adaptor for the receptor ERBB2/HER2 in epithelia. ERBIN contains 16 leucine-rich repeats (LRRs) in its amino terminus and a PDZ (PSD-95/DLG/ZO-1) domain at its carboxy terminus, and belongs to a new PDZ protein family. The PDZ domain directly and specifically interacts with ERBB2/ HER2. ERBIN and ERBB2/HER2 colocalize to the lateral membrane of human intestinal epithelial cells. The ERBIN-binding site in ERBB2/HER2 has a critical role in restricting this receptor to the basolateral membrane of epithelial cells, as mutation of the ERBIN-binding site leads to the mislocalization of the receptor in these cells. We suggest that ERBIN acts in the localization and signalling of ERBB2/HER2 in epithelia.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 50 条
  • [31] The erbB2/HER2/neu receptor polymorphism IIe655Val and breast cancer
    Cox, DG
    Hankinson, SE
    Hunter, DJ
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (07): : 447 - 450
  • [32] Identification of autocrine motility factor (AMF) receptor, HER2 (ErbB2) in breast cancer cells
    Kho, Dhonghyo
    CANCER RESEARCH, 2012, 72
  • [33] HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
    Ralf Landgraf
    Breast Cancer Research, 9
  • [34] ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
    David F. Stern
    Journal of Mammary Gland Biology and Neoplasia, 2008, 13
  • [35] Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
    Harari, D
    Yarden, Y
    ONCOGENE, 2000, 19 (53) : 6102 - 6114
  • [36] HER2/ERBB2 Testing in Breast Carcinoma by Next Generation Sequencing
    Wong, Adele
    Bhan, Atul
    Lennerz, Jochen K.
    Brachtel, Elena
    MODERN PATHOLOGY, 2017, 30 : 522A - 522A
  • [37] Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
    Daniel Harari
    Yosef Yarden
    Oncogene, 2000, 19 : 6102 - 6114
  • [38] Future options in the treatment of ErbB2 (HER2)-positive breast cancer
    Fumoleau, Pierre
    EJC SUPPLEMENTS, 2008, 6 (05): : 25 - 31
  • [39] Tucatinib HER2 (ErbB2) inhibitor Treatment of breast and colorectal cancer
    Patil, T.
    Shagisultanova, E.
    Borges, V. F.
    DRUGS OF THE FUTURE, 2019, 44 (01) : 11 - 19
  • [40] When Tumor Suppressor TGFβ Meets the HER2 (ERBB2) Oncogene
    Chow, Amy
    Arteaga, Carlos L.
    Wang, Shizhen Emily
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2011, 16 (02) : 81 - 88